Germany’s BioNTech to buy Chinese firm with promising cancer drug
Berlin, Germany – Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its cancer drug development by agreeing to buy Chinese firm Biotheus. The Mainz-based group said in a statement on Wednesday it will pay up to $950 million, including an upfront payment of $800 million. The takeover…
